|
Medtronic Plc (NYSE: MDT) |
|
|
|
| |
Medtronic Plc Income Statement Quarterly
MDT
|
Select the Financial Report: |
Period: |
|
|
|
INCOME STATEMENT
(Quarterly GAAP In millions $) |
(Jan 24 2025)
Q3 2025 |
(Oct 25 2024)
Q2 2025 |
(Jul 26 2024)
Q1 2025 |
(Apr 26 2024)
Q4 2024 |
(Jan 26 2024)
Q3 2024 |
| Revenue From Contract With Customer Excluding Assessed Tax |
8,292.00 |
8,403.00 |
7,915.00 |
|
8,089.00 |
| Revenue From Contract With Customer Excluding Assessed Tax |
- |
- |
- |
|
- |
| Total Revenue |
8,292.00 |
8,403.00 |
7,915.00 |
8,589.00 |
8,089.00 |
| Cost of Goods and Services Sold |
2,779.00 |
2,946.00 |
2,761.00 |
3,045.00 |
2,782.00 |
| Gross
Profit |
5,513.00 |
5,457.00 |
5,154.00 |
5,544.00 |
5,307.00 |
| Selling, Administration, Marketing |
2,717.00 |
2,757.00 |
2,655.00 |
2,764.00 |
2,673.00 |
| Depriciation & Amortization |
416.00 |
413.00 |
414.00 |
420.00 |
419.00 |
| Research and Development Expense (Excluding Acquired in Process Cost) |
675.00 |
697.00 |
676.00 |
674.00 |
695.00 |
| Restructuring |
- |
- |
- |
- |
- |
| Other operatinig exp. /-income |
-6.00 |
-35.00 |
3.00 |
758.00 |
17.00 |
| Unusual Income/ -Expense |
- |
- |
- |
- |
- |
| Loss Contingency Accrual Provision |
22.00 |
- |
81.00 |
-65.00 |
- |
| Restructuring Charges Net Of Restructuring Reversals Including Cost Of Product Sold Impact |
43.00 |
30.00 |
47.00 |
-60.00 |
20.00 |
| Total operating costs including COS |
6,646.00 |
6,808.00 |
6,637.00 |
7,536.00 |
6,606.00 |
| Operating income/-loss
|
1,646.00 |
1,595.00 |
1,278.00 |
1,053.00 |
1,483.00 |
|
Other Deductions / - Income |
| Interest expense |
- |
- |
- |
203.00 |
188.00 |
| Interest income |
- |
- |
- |
- |
- |
| Net interest expense/-income |
- |
- |
- |
203.00 |
188.00 |
| Loss/ -Gain on Investment |
- |
- |
- |
- |
- |
| Sale of Business |
- |
- |
- |
- |
- |
| Sale of Assets |
- |
- |
- |
- |
- |
| Financing Loss/ -Income |
- |
- |
- |
- |
- |
| Other loss/ -income |
-73.00 |
-173.00 |
-157.00 |
-6.00 |
-177.00 |
| Interest Expense Nonoperating |
179.00 |
209.00 |
167.00 |
- |
- |
| Total costs & expenses |
6,752.00 |
6,844.00 |
6,647.00 |
7,733.00 |
6,617.00 |
| Income /-loss before income taxes |
1,540.00 |
1,559.00 |
1,268.00 |
856.00 |
1,472.00 |
| Income taxes expenses/-benefit |
237.00 |
281.00 |
220.00 |
196.00 |
135.00 |
| Income after income taxes |
1,303.00 |
1,278.00 |
1,049.00 |
660.00 |
1,337.00 |
| Net income/-loss
of other equity |
- |
- |
1.00 |
- |
- |
| Income/-loss
from cont. Ops. |
1,303.00 |
1,278.00 |
1,049.00 |
660.00 |
1,337.00 |
| Accounting change |
- |
- |
- |
- |
- |
| Discontinued operations |
- |
- |
- |
- |
- |
| Extraordinary items |
- |
- |
- |
- |
- |
| Net Income/-loss |
1,303.00 |
1,278.00 |
1,049.00 |
660.00 |
1,337.00 |
| Noncontrolling interests |
-9.00 |
-9.00 |
-6.00 |
-5.00 |
-15.00 |
| Prefered dividends |
- |
- |
- |
- |
- |
| Other |
- |
- |
- |
- |
- |
| Income/-loss to shareholder |
1,294.00 |
1,270.00 |
1,042.00 |
654.00 |
1,322.00 |
| EBIT |
1,540.00 |
1,559.00 |
1,268.00 |
1,059.00 |
1,660.00 |
| EBITD |
2,224.00 |
2,234.00 |
1,930.00 |
1,713.00 |
2,309.00 |
| EBITDA |
2,224.00 |
2,234.00 |
1,930.00 |
1,713.00 |
2,309.00 |
| Per
Share (GAAP Quarterly, in $) |
(Jan 24 2025)
Q3 2025 |
(Oct 25 2024)
Q2 2025 |
(Jul 26 2024)
Q1 2025 |
(Apr 26 2024)
Q4 2024 |
(Jan 26 2024)
Q3 2024 |
| Basic EPS (excl. extra
items) |
1.01 |
0.99 |
0.81 |
0.50 |
0.99 |
| Extraordinary items |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
| Basic Net EPS |
1.01 |
0.99 |
0.81 |
0.50 |
0.99 |
| Basic shares outstanding (Mill.
of Units) |
1,282.40 |
1,282.40 |
1,293.30 |
1,320.40 |
1,329.70 |
| EPS other shares |
- |
- |
- |
- |
- |
| Diluted Net EPS |
1.01 |
0.99 |
0.80 |
0.49 |
0.99 |
| Diluted average shares (Mill.
of Units) |
1,286.20 |
1,286.90 |
1,296.50 |
1,331.88 |
1,331.70 |
| Dividend per share |
0.697 |
0.697 |
0.693 |
0.685 |
0.689 |
|
